Pharmacological suppression of TNK2 prevented the activation of MAPK/ERK signaling in juvenile myelomonocytic leukemia (JMML) and reduced the size of the tumor [51]. The gene discussed is MAPK1; the disease is juvenile myelomonocytic leukemia.